NewAmsterdam Pharma completes $196m Series A funding for phase 3 development programme
The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor,